Aktienanalyse zu InterCure Ltd (INCR)INCRInterCure Ltd

InterCure Ltd. is an Israel-based company engaged in the medical cannabis industry. Through its wholly owned subsidiary, Canndoc Ltd., the Company cultivates, produces, processes, markets, and distributes medical cannabis products. Its operations include the development and manufacture of pharmaceutical-grade medical cannabis products produced in accordance with Good Manufacturing Practice (GMP) standards. The Company offers a range of cannabis-based products for medical use and operates across various stages of the medical cannabis value chain, including cultivation, manufacturing, logistics, distribution, and retail activities. In addition, the Company is involved in the import, export, and commercialization of medical cannabis products and related healthcare solutions in Israel and selected international markets. It operates in the Healthcare sector.

InterCure Ltd is not a strong buy at the moment due to its current price of 4.05, which is close to its 52-week low of 3.40, and an RSI of 28.77 indicating oversold conditions. While the forward P/E ratio is a low 6.18, suggesting potential value, the company has reported significant losses, with a net income margin of -24.26% in the latest quarter, which raises concerns about its profitability and financial health.

12 analysts cover INCR: 8 rate it Buy, 4 Hold and 0 Sell.